In another phase I/II trial [36], autologous DCs loaded with WT1 and PRAME (Preferentially Expressed Antigen of Melanoma), another antigen expressed on leukemic cells, were used to vaccinate 20 AML patients in CR considered unfit for transplantation. Here, WT1 is linked to acute myeloid leukemia.